文献速递肾小球疾病

抗磷脂酶A2受体抗体相关膜性肾病缓解预测:GEMRITUX、MENTOR和STARMEN试验的二次分析

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-04-14

该研究基于187例抗磷脂酶A2受体抗体相关膜性肾病患者,从三项临床试验数据推导逻辑回归模型,预测12个月蛋白尿缓解。3个月和6个月模型预测性能相似,均优于基线模型,且在不同治疗方案亚组中保持稳定。

要点

  • 3个月和6个月预测模型均可用于预测12个月蛋白尿缓解,3个月模型可更早评估。
  • 模型预测性能在不同治疗方案(支持治疗、利妥昔单抗、钙调磷酸酶抑制剂、环磷酰胺)亚组中保持稳定。
  • 3个月和6个月模型在阈值概率≤31%时净获益相似,内部验证后性能保持。

核心结论

  • 在抗磷脂酶A2受体抗体相关膜性肾病患者中,治疗3或6个月后可使用3个月或6个月预测模型预测12个月缓解状态。

研究设计与样本

  • 研究为对GEMRITUX、MENTOR和STARMEN三项临床试验的二次分析,纳入187例基线抗体水平≥14 RU/ml的患者。
  • 使用逻辑回归模型预测12个月蛋白尿缓解,预测因子包括男性、基线及血清白蛋白、蛋白尿和抗体水平变化,含或不含eGFR变化。

主要发现

  • 12个月时107例患者达到蛋白尿缓解。
  • 与基线模型相比,3个月和6个月模型拟合更优:AIC为186/158 vs 225,R2为52.7%/62.4% vs 25.8%。
  • 3个月和6个月模型区分度更高:C统计量为0.87和0.91 vs 0.75,P<0.001;校准更优:集成校准指数为0.89%/2.22% vs 2.51%。
  • 3个月和6个月模型预测性能无一致差异,决策曲线分析显示阈值概率至31%时净获益相似。
  • 内部验证(乐观校正)后预测性能保持,且在不同治疗亚组中维持。

临床怎么用

  • 临床可在治疗3或6个月时使用这些模型评估抗磷脂酶A2受体抗体相关膜性肾病患者12个月缓解概率,辅助治疗决策。

局限性

  • 研究为二次分析,样本量187例,需外部验证确认模型适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In phospholipase A2 receptor-membranous nephropathy, clinical variables and antibody levels over 3 or 6 months of treatment were predictors of remission at 1 year. Prediction models at 3 and 6 months had similar performance predicting remission, with the 3-month model allowing for earlier assessment of response. The 3-month and 6-month prediction models could be applied in those treated with supportive therapy, rituximab, calcineurin inhibitors, or cyclophosphamide. BACKGROUND: In patients with antiphospholipase A2 receptor antibody–associated membranous nephropathy, there is currently no accepted method to predict an individual's probability of remission after treatment with immunosuppression or supportive therapy using changes in antibody levels and clinical variables during the first 3–6 months of therapy. METHODS: Using a cohort of 187 patients from the Glomérulopathie extramembraneuse rituximab, Membranous Nephropathy Trial of Rituximab, and Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in primary Membranous Nephropathy clinical trials with antibody levels at baseline ≥14 RU/ml, we derived logistic regression models to predict proteinuria remission at 12 months that can be used at baseline or after 3 or 6 months of treatment. Treatment exposures in the trials included supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Predictors in the models included male sex and baseline and changes in serum albumin, proteinuria, and antibody levels, with or without changes in eGFR. RESULTS: Proteinuria remission at 12 months was achieved in 107 patients. Compared with the model at baseline, the 3-month and 6-month models had better model fit with lower Akaike information criterion (186/158 versus 225) and higher R2 (52.7%/62.4% versus 25.8%), better discrimination with higher C-statistic (0.87 and 0.91 versus 0.75, P < 0.001), and better calibration with lower integrated calibration index (0.89%/2.22% versus 2.51%). The 3-month and 6-month models had no consistent difference in prediction performance, and decision curve analysis demonstrated similar net benefit for treatment decisions based on either model up to a threshold probability of 31%. Prediction performance was similar after internal validation using optimism correction. Prediction performance was maintained within subgroups of different treatment regimens, including supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. CONCLUSIONS: Either the 3-month or 6-month models can be used in patients with antiphospholipase A2 receptor antibody associated membranous nephropathy after 3 or 6 months of treatment with a variety of immunosuppression or supportive therapy to predict remission status at 12 months.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Barbour SJ, Ronco P, Praga M, et al. Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials. Clin J Am Soc Nephrol. 2025. PMID: 40228233. doi:10.2215/CJN.0000000694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。